Control group:Docetaxel 75mg/m2, first day, 21 days a week

2 trials

Sponsors

Nanyang Central Hospital

Conditions

Non-small Cell Lung Canceresophageal cancer

Phase 4

An exploratory, open and multicenter clinical study for Androtinib combined with docetaxel versus docetaxel as second-line monotherapy for advanced esophageal squamous cell carcinoma

Active, not recruitingChiCTR1800020008

Nanyang Central Hospitalesophageal cancer

Start: 2019-05-01Updated: 2018-12-18

Clinical Study for Anlotinib Hydrochloride Combined with Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer

RecruitingChiCTR1900023723

Nanyang Central HospitalNon-small Cell Lung Cancer

Start: 2019-06-01Updated: 2019-06-11